Fig. 4.
The antitumor activity of immunocasp-3 on PSMA-overexpressing tumors in vivo. a: Tumor volume and tumor growth curves in mice injected with lipofectamine-encapsulated immunocasp-3 gene or pCMV plasmid or with immunocasp-3 gene-modified Jurkat cells or control Jurkat cells. b: Survival of mice after treatment, as described in a. c: Nude mice with LNCaP tumor received 3 weekly intravenous. injections of 2 × 106 immunocasp-3 gene-modified Jurkat cells. Tissues were then subjected to immunohistochemical analysis with an anti-caspase-3 antibody